Seqirus USA Inc.

Dec 09, 2019

New Data Demonstrate that FLUAD® (Influenza Vaccine, Adjuvanted) Significantly Reduces Hospitalization Risk for Adults 65+ Living in U.S. Nursing Homes Compared to Standard Trivalent Influenza Vaccine

Aug 31, 2019

Seqirus Presents New Scientific Data Comparing Circulating Influenza B Viruses With Both Cell-Based and Egg-Based Influenza B Reference Viruses

Aug 30, 2019

Seqirus Presents New Clinical Data that Reinforce the Ability of MF59® Adjuvanted Seasonal and Pandemic Influenza Vaccines to Increase Immune Response

Apr 15, 2019

Seqirus Announces Further Advances in Cell-Based Influenza Vaccine Technology

Nov 16, 2018

Seqirus Releases Real-World Data Indicating Significantly Greater Effectiveness of Cell-Based Seasonal Influenza Vaccines Compared to Standard Influenza Vaccine Options

Oct 23, 2018

Seqirus Receives FDA Approval of AFLURIA® QUADRIVALENT (Influenza Vaccine) for People Six Months of Age and Older in the U.S.

Aug 08, 2018

Seqirus Begins Shipping 2018-2019 Influenza Vaccines to the U.S. Market